These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy. Vaughan DE; Goldhaber SZ; Kim J; Loscalzo J Circulation; 1987 Jun; 75(6):1200-3. PubMed ID: 3105914 [TBL] [Abstract][Full Text] [Related]
4. Thrombolytic therapy of acute pulmonary embolism: current status and future potential. Goldhaber SZ; Meyerovitz MF; Markis JE; Kim D; Kessler CM; Sharma GV; Vaughan DE; Selwyn AP; Dawley DL; Loscalzo J J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):96B-104B. PubMed ID: 3117862 [TBL] [Abstract][Full Text] [Related]
5. Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. Come PC; Kim D; Parker JA; Goldhaber SZ; Braunwald E; Markis JE J Am Coll Cardiol; 1987 Nov; 10(5):971-8. PubMed ID: 2959713 [TBL] [Abstract][Full Text] [Related]
6. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Goldhaber SZ; Agnelli G; Levine MN Chest; 1994 Sep; 106(3):718-24. PubMed ID: 8082347 [TBL] [Abstract][Full Text] [Related]
7. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. Goldhaber SZ; Kessler CM; Heit JA; Elliott CG; Friedenberg WR; Heiselman DE; Wilson DB; Parker JA; Bennett D; Feldstein ML J Am Coll Cardiol; 1992 Jul; 20(1):24-30. PubMed ID: 1607532 [TBL] [Abstract][Full Text] [Related]
8. Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning. Parker JA; Markis JE; Palla A; Goldhaber SZ; Royal HD; Tumeh S; Kim D; Rustgi AK; Holman BL; Kolodny GM Radiology; 1988 Feb; 166(2):441-5. PubMed ID: 3122266 [TBL] [Abstract][Full Text] [Related]
9. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Goldhaber SZ; Kessler CM; Heit J; Markis J; Sharma GV; Dawley D; Nagel JS; Meyerovitz M; Kim D; Vaughan DE Lancet; 1988 Aug; 2(8606):293-8. PubMed ID: 2899718 [TBL] [Abstract][Full Text] [Related]
10. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Goldhaber SZ; Haire WD; Feldstein ML; Miller M; Toltzis R; Smith JL; Taveira da Silva AM; Come PC; Lee RT; Parker JA Lancet; 1993 Feb; 341(8844):507-11. PubMed ID: 8094768 [TBL] [Abstract][Full Text] [Related]
11. Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity. Lami D; Cellai AP; Antonucci E; Fiorillo C; Becatti M; Grifoni E; Cenci C; Marcucci R; Mannini L; Miniati M; Abbate R; Prisco D Thromb Res; 2014 Sep; 134(3):737-41. PubMed ID: 25074740 [TBL] [Abstract][Full Text] [Related]
12. Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism. Tebbe U; Seifried E; Carlsson J; Tanswell P Blood Coagul Fibrinolysis; 1992 Aug; 3(4):475-80. PubMed ID: 1420824 [TBL] [Abstract][Full Text] [Related]
13. [Chronic effects of 100 mg/2 hours recombinant tissue-type plasminogen activator therapy regimen for patients with acute pulmonary thromboembolism]. Li ZP; Xu B; Jiang R; Li JL; Jiang X; Sun ML; Jing ZC; Li YP Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Mar; 41(3):224-8. PubMed ID: 23879948 [TBL] [Abstract][Full Text] [Related]
14. Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics. Prewitt RM; Shiffman F; Greenberg D; Cook R; Ducas J Circulation; 1989 Apr; 79(4):929-38. PubMed ID: 2494007 [TBL] [Abstract][Full Text] [Related]
15. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Dalla-Volta S; Palla A; Santolicandro A; Giuntini C; Pengo V; Visioli O; Zonzin P; Zanuttini D; Barbaresi F; Agnelli G J Am Coll Cardiol; 1992 Sep; 20(3):520-6. PubMed ID: 1512328 [TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism. Zhang LY; Gao BA; Jin Z; Xiang GM; Gong Z; Zhang TT; Lu HF; Wang YQ; Gong Y; Lu C; Huang WL Saudi Med J; 2018 Nov; 39(11):1090-1095. PubMed ID: 30397707 [TBL] [Abstract][Full Text] [Related]
18. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Verstraete M; Miller GA; Bounameaux H; Charbonnier B; Colle JP; Lecorf G; Marbet GA; Mombaerts P; Olsson CG Circulation; 1988 Feb; 77(2):353-60. PubMed ID: 3123091 [TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest; 1990 Mar; 97(3):528-33. PubMed ID: 2106408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]